1. Home
  2. NAN vs CRDF Comparison

NAN vs CRDF Comparison

Compare NAN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAN
  • CRDF
  • Stock Information
  • Founded
  • NAN 1999
  • CRDF 1999
  • Country
  • NAN United States
  • CRDF United States
  • Employees
  • NAN N/A
  • CRDF N/A
  • Industry
  • NAN Investment Managers
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NAN Finance
  • CRDF Health Care
  • Exchange
  • NAN Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • NAN 352.5M
  • CRDF 288.7M
  • IPO Year
  • NAN N/A
  • CRDF N/A
  • Fundamental
  • Price
  • NAN $11.39
  • CRDF $3.29
  • Analyst Decision
  • NAN
  • CRDF Strong Buy
  • Analyst Count
  • NAN 0
  • CRDF 4
  • Target Price
  • NAN N/A
  • CRDF $12.00
  • AVG Volume (30 Days)
  • NAN 74.6K
  • CRDF 1.1M
  • Earning Date
  • NAN 01-01-0001
  • CRDF 05-01-2025
  • Dividend Yield
  • NAN 4.37%
  • CRDF N/A
  • EPS Growth
  • NAN N/A
  • CRDF N/A
  • EPS
  • NAN N/A
  • CRDF N/A
  • Revenue
  • NAN N/A
  • CRDF $683,000.00
  • Revenue This Year
  • NAN N/A
  • CRDF N/A
  • Revenue Next Year
  • NAN N/A
  • CRDF N/A
  • P/E Ratio
  • NAN N/A
  • CRDF N/A
  • Revenue Growth
  • NAN N/A
  • CRDF 39.96
  • 52 Week Low
  • NAN $9.11
  • CRDF $2.01
  • 52 Week High
  • NAN $11.34
  • CRDF $6.38
  • Technical
  • Relative Strength Index (RSI)
  • NAN 41.14
  • CRDF 36.56
  • Support Level
  • NAN $11.32
  • CRDF $3.65
  • Resistance Level
  • NAN $11.52
  • CRDF $3.88
  • Average True Range (ATR)
  • NAN 0.10
  • CRDF 0.26
  • MACD
  • NAN -0.01
  • CRDF -0.06
  • Stochastic Oscillator
  • NAN 51.22
  • CRDF 2.59

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Share on Social Networks: